Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
431 stopped studies mapped to Liver Carcinoma and descendants · 94% state a reason
Over the 431 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03990974 | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC…(HCC) | Phase 3 | suspended | Jun 19, 2019 | Sun Yat-sen University | There were difficulties in implementation | Other (stated, no rule matched) |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | Phase 2 | withdrawn | Jul 19, 2019 | National Cancer Institute (NCI) | slow/insufficient accrual. | Enrollment / accrual |
| NCT01760616 | Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical… | Phase 4 | terminated | Jan 4, 2013 | Qidong Gaitianli Medicines Co., Ltd | difficult to recruit patients | Enrollment / accrual |
| NCT03079778 | Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy…(TACERT) | N/A | withdrawn | Mar 14, 2017 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Opened up a separate Clinicaltrials.gov trial form, study ID TACE | Other (stated, no rule matched) |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay… | Phase 2 | withdrawn | Oct 20, 2015 | Zhejiang University | no patients enrolled | Enrollment / accrual |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion… | Phase 3 | terminated | Aug 15, 2016 | Sun Yat-sen University | Midterm analysis showed negative results. | Other (stated, no rule matched) |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell… | Phase 1 | withdrawn | Jul 14, 2017 | National Cancer Institute (NCI) | Other - Drug Manufacturer decision to close study | Drug supply |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | Phase 1 / Phase 2 | withdrawn | Aug 15, 2013 | Mirror Biologics, Inc. | interventional radiologist suffered stroke and unable to perform RFA procedure | Other (stated, no rule matched) |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | Phase 1 / Phase 2 | withdrawn | Nov 26, 2013 | Mirror Biologics, Inc. | Study site change to Thailand | Other (stated, no rule matched) |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver… | Phase 2 | withdrawn | Nov 13, 2014 | A2 Healthcare Taiwan Corporation | At sponsor's discretion | Other (stated, no rule matched) |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With… | Phase 2 / Phase 3 | withdrawn | Aug 5, 2019 | Shi Ming | Bristol-Myers Squibb company terminated this study | Sponsor / business decision |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular…(NUANCE) | Phase 1 | terminated | Dec 26, 2017 | University of Utah | PI decided to terminate due to low/slow accrual | Enrollment / accrual |
| NCT03433703 | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following… | Phase 2 | terminated | Feb 14, 2018 | Eisai Inc. | Study recruitment was stopped due to difficulty in enrolling the targeted number of participants. | Enrollment / accrual |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With… | Phase 1 | withdrawn | Nov 11, 2014 | University of Hawaii | Closed due to no accrual | Enrollment / accrual |
| NCT02323360 | A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment… | N/A | terminated | Dec 23, 2014 | Istituto Clinico Humanitas | too slow enrollment | Enrollment / accrual |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | Phase 1 | withdrawn | Nov 13, 2018 | Lee's Pharmaceutical Limited | Sponsor's commercial decision | Other (stated, no rule matched) |
| NCT02147301 | TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve | N/A | terminated | May 26, 2014 | University of California, San Francisco | Risk to benefit ratio is not acceptable | Other (stated, no rule matched) |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of… | Phase 2 | withdrawn | Oct 27, 2016 | Shanghai Proton and Heavy Ion Center | enrollment was too slow | Enrollment / accrual |
| NCT01817205 | Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular… | N/A | terminated | Mar 25, 2013 | Chinese University of Hong Kong | poor case accrual | Enrollment / accrual |
| NCT01806740 | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients…(DCE-MRI) | Phase 4 | terminated | Mar 7, 2013 | Guerbet | The planned number of enrolled patients was not reached. | Enrollment / accrual |
| NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With…(ORIENTAL) | Phase 3 | terminated | Nov 4, 2011 | Taiho Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Phase 2 | terminated | Oct 24, 2017 | Effector Therapeutics | The study was terminated due to change in focus of the development program | Other (stated, no rule matched) |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | Phase 1 | terminated | Nov 21, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd. | Will study new T-cell construct for the same indication | Other (stated, no rule matched) |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin…(LD-FOX4/HCC) | Phase 2 / Phase 3 | withdrawn | Aug 19, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for… | Phase 2 / Phase 3 | withdrawn | Aug 27, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy… | Phase 2 / Phase 3 | withdrawn | Oct 22, 2015 | Guangxi Medical University | not stated | Not stated |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | Phase 2 | withdrawn | Apr 18, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing… | N/A | withdrawn | Oct 3, 2017 | University of Southern California | Accrual issue | Enrollment / accrual |
| NCT01290523 | Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With… | N/A | terminated | Feb 7, 2011 | University of California, San Francisco | Off study clinical use of Y90 glass microspheres (TheraSphere) | Other (stated, no rule matched) |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | Phase 2 | withdrawn | Dec 14, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | Phase 2 | withdrawn | Dec 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | Phase 2 | withdrawn | Jan 14, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | Phase 3 | withdrawn | Nov 16, 2018 | Sun Yat-sen University | No paritcipants enrolled | Enrollment / accrual |
| NCT03782831 | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | Phase 2 | withdrawn | Dec 20, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven… | Phase 3 | withdrawn | Jan 3, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | Phase 2 | withdrawn | Nov 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT01676194 | Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma(CATCH) | Phase 3 | terminated | Aug 30, 2012 | Rennes University Hospital | insufficient recruitment | Enrollment / accrual |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary… | Phase 2 | terminated | Oct 31, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Oct 17, 2014 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication | Other (stated, no rule matched) |
| NCT00465842 | Protein Biomarker in Hepatocellular Carcinoma | — | terminated | Apr 25, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Loss of funding due to difficulty with recruitment and participant retention. | Enrollment / accrual |
| NCT02748304 | Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With… | N/A | terminated | Apr 22, 2016 | Fudan University | The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose… | Enrollment / accrual |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2016 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | Phase 2 | suspended | Dec 19, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT01600196 | Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous… | Phase 4 | terminated | May 16, 2012 | Sun Yat-sen University | not stated | Not stated |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a… | Phase 2 / Phase 3 | terminated | Aug 19, 2014 | Sun Yat-sen University | protocol violation | Other (stated, no rule matched) |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein… | Phase 1 / Phase 2 | terminated | Jan 27, 2017 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication. | Other (stated, no rule matched) |
| NCT02787954 | Prospective Tumor Response Evaluation(Liver) | — | terminated | Jun 1, 2016 | The University of Texas Health Science Center, Houston | PI transferred to another institution and did not take this study with him. | Other (stated, no rule matched) |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | Phase 2 | terminated | Oct 2, 2014 | Allina Health System | lack of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 25, 2020source: clinicaltrials